Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.10.040
Junhao Chen, Haifeng Wang, Shi Fu
Section snippets
Authors’ contributions
Junhao Chen: conceptualization and manuscript draft. Haifeng Wang: supporting role in revision for important intellectual content. Shi Fu: critical revision for important intellectual content, final approval.
Financial support
None
Declaration of Competing Interest
The authors of this study declare that they do not have any conflict of interest.
{"title":"Rethinking Methodology and Data Integrity in Mendelian Randomization: Insights from Air Pollution and MASLD Research","authors":"Junhao Chen, Haifeng Wang, Shi Fu","doi":"10.1016/j.jhep.2024.10.040","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.040","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions</h2>Junhao Chen: conceptualization and manuscript draft. Haifeng Wang: supporting role in revision for important intellectual content. Shi Fu: critical revision for important intellectual content, final approval.</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors of this study declare that they do not have any conflict of interest.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.10.041
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Section snippets
AUTHOR CONTRIBUTIONS
RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.
DISCLOSURES/ CONFLICT OF INTEREST STATEMENT
MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.
DATA AVAILABILITY STATEMENT
The data from this study is available from the corresponding author upon reasonable request.
Funding
Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.
{"title":"Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.10.041","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.041","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to make a decision for the use of plasma exchange in patients with acute liver failure?","authors":"Xiang-Yu Han, Hui-ru Qi","doi":"10.1016/j.jhep.2024.10.038","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.038","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>The author received no financial support to produce this manuscript.</section></section><section><section><h2>Authors’ contributions</h2>Xiang-Yu Han: manuscript writing; Hui-ru Qi: critical revision</section></section><section><section><h2>Declaration of Competing Interest</h2>The author declare no conflicts of interest.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Plasma exchange in Acute liver failure: The jury is still out!","authors":"Sagnik Biswas, Shekhar Swaroop","doi":"10.1016/j.jhep.2024.10.037","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.037","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial disclosures funding</h2>None</section></section><section><section><h2>Conflicts of interest COI</h2>The authors declare no conflicts of interest</section></section><section><section><h2>Authors contributions author-disclosure</h2>SB and SS wrote the initial draft. S revised the paper. All authors approved the final manuscript.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142594290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.10.042
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Section snippets
Author Contributions
RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.
Disclosures/ Conflict Of Interest Statement
MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.
Data Availability Statement
The data from this study is available from the corresponding author upon reasonable request.
Funding
Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.
{"title":"Reply to: “Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio”","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.10.042","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.042","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author Contributions</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>Disclosures/ Conflict Of Interest Statement</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>Data Availability Statement</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.09.036
Vincenzo La Mura, Mauro Bernardi, Paolo Angeli
Professor Francesco Salerno was a brilliant man who dedicated his life to helping patients with advanced chronic liver diseases and who was internationally renowned for his studies on the pathophysiology of cirrhosis and its complications, as well as the management of patients with ascites, renal dysfunction and bacterial infections. He contributed to the foundation of key international groups such as the International Club of Ascites, the CLIF consortium, and the Baveno group.
弗朗切斯科-萨勒诺教授是一位杰出的人，他毕生致力于帮助晚期慢性肝病患者，在肝硬化病理生理学及其并发症的研究，以及腹水、肾功能障碍和细菌感染患者的治疗方面享誉国际。他为国际腹水俱乐部（International Club of Ascites）、CLIF 联合会和巴韦诺小组等重要国际组织的成立做出了贡献。
{"title":"In Memoriam: Prof. Francesco Salerno","authors":"Vincenzo La Mura, Mauro Bernardi, Paolo Angeli","doi":"10.1016/j.jhep.2024.09.036","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.09.036","url":null,"abstract":"Professor Francesco Salerno was a brilliant man who dedicated his life to helping patients with advanced chronic liver diseases and who was internationally renowned for his studies on the pathophysiology of cirrhosis and its complications, as well as the management of patients with ascites, renal dysfunction and bacterial infections. He contributed to the foundation of key international groups such as the International Club of Ascites, the CLIF consortium, and the Baveno group.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.10.039
Valentin Coirier, Florent Artru, Christophe Camus
Section snippets
Declaration of Competing Interest
none
Financial disclosure
none
Author contributions
all authors contributed equally to the manuscript in terms of concept, writing, editing.
章节片段竞争利益声明无财务披露无作者贡献所有作者在构思、写作和编辑方面对稿件做出了同等贡献。
{"title":"Late use of Plasma Exchange in Acute Liver Failure: The Battle is Lost?","authors":"Valentin Coirier, Florent Artru, Christophe Camus","doi":"10.1016/j.jhep.2024.10.039","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.039","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Declaration of Competing Interest</h2>none</section></section><section><section><h2>Financial disclosure</h2>none</section></section><section><section><h2>Author contributions</h2>all authors contributed equally to the manuscript in terms of concept, writing, editing.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.jhep.2024.10.024
Jessica Ann Musto, Randall Brown, Michael Ronan Lucey
In order to understand and curb the harms related to alcohol, it will be necessary to think beyond patterns of use that meet criteria for a diagnosis of alcohol use disorder, or addiction. Current research suggests that regular daily alcohol use does not confer a health benefit, and for many persons, even relatively low consumption is associated with a health risk. Determining a safe limit for alcohol consumption is challenging both for the individual person and for society. We conclude that excessive drinking is always risky. We provide a list of circumstances, such as chronic illness, driving a vehicle, or pregnancy where persons should be advised to abstain from alcohol. We recognize the need to encourage less consumption of alcohol, particularly in young adults, and in older adults with co-morbid conditions particularly when taking multiple medications. Finally, we offer the modest proposal that, for persons without the contributing negative influences described above, consumption which adheres to one drink per session, with interspersed abstinent days, does not constitute a meaningful risk to health.
{"title":"Is there a safe limit for consumption of alcohol?","authors":"Jessica Ann Musto, Randall Brown, Michael Ronan Lucey","doi":"10.1016/j.jhep.2024.10.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.024","url":null,"abstract":"In order to understand and curb the harms related to alcohol, it will be necessary to think beyond patterns of use that meet criteria for a diagnosis of alcohol use disorder, or addiction. Current research suggests that regular daily alcohol use does not confer a health benefit, and for many persons, even relatively low consumption is associated with a health risk. Determining a safe limit for alcohol consumption is challenging both for the individual person and for society. We conclude that excessive drinking is always risky. We provide a list of circumstances, such as chronic illness, driving a vehicle, or pregnancy where persons should be advised to abstain from alcohol. We recognize the need to encourage less consumption of alcohol, particularly in young adults, and in older adults with co-morbid conditions particularly when taking multiple medications. Finally, we offer the modest proposal that, for persons without the contributing negative influences described above, consumption which adheres to one drink per session, with interspersed abstinent days, does not constitute a meaningful risk to health.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31DOI: 10.1016/j.jhep.2024.07.032
Didier Samuel
Liver transplantation (LT) is an established life-saving procedure. The field of LT has changed in the past 10 years from several perspectives, with the expansion of indications, transplantation of patients with acute-on-chronic liver failure, evolution of transplant oncology, the use of donations after cardiac death, new surgical techniques, and prioritisation of recipients on the waiting list. In addition, the advent of organ perfusion machines, the recognition of new forms of rejection, and the attention paid to the transition from paediatric to adult patients, have all improved the management of LT recipients. The purpose of the EASL guidelines presented here is not to cover all aspects of LT but to focus on developments since the previous EASL guidelines published in 2016.
{"title":"EASL Clinical Practice Guidelines on liver transplantation","authors":"Didier Samuel","doi":"10.1016/j.jhep.2024.07.032","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.07.032","url":null,"abstract":"Liver transplantation (LT) is an established life-saving procedure. The field of LT has changed in the past 10 years from several perspectives, with the expansion of indications, transplantation of patients with acute-on-chronic liver failure, evolution of transplant oncology, the use of donations after cardiac death, new surgical techniques, and prioritisation of recipients on the waiting list. In addition, the advent of organ perfusion machines, the recognition of new forms of rejection, and the attention paid to the transition from paediatric to adult patients, have all improved the management of LT recipients. The purpose of the EASL guidelines presented here is not to cover all aspects of LT but to focus on developments since the previous EASL guidelines published in 2016.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30DOI: 10.1016/j.jhep.2024.10.031
En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang
Background & Aims
The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.
Methods
Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.
Results
In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.
Conclusions
While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.
{"title":"Liver Cancer in 2021: Global Burden of Disease Study","authors":"En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang","doi":"10.1016/j.jhep.2024.10.031","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.031","url":null,"abstract":"<h3>Background & Aims</h3>The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.<h3>Methods</h3>Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.<h3>Results</h3>In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.<h3>Conclusions</h3>While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：